Table 1.
ICI Agent | Complement PD-L1 Ab | Ab Host Species | Platform | Detection System | Diagnostic Cut-Off |
---|---|---|---|---|---|
Pembrolizumab [59,112] | 22C3 | murine | Dako autostainer Link 48 | EnVision FLEX visualization system |
TC or IC ≥1% (CPS) |
Nivolumab [18] | 28-8 | rabbit | Dako Autostainer Link 48 | OptiView DAB IHC Detection Kit | TC >1%, TC >5% |
Atezolizumab [123] | SP142 | rabbit | Ventana Benchmark Ultra | OptiView DAB IHC Detection Kit | TC: ≥ 5%, IC: ≥ 5% |
Durvalumab [60] | SP263 | rabbit | Ventana Benchmark Ultra | OptiView DAB IHC Detection Kit/ OptiView Amplification Kit |
TC: ≥ 25% |
Avelumab [124] | 73-10 | rabbit | Dako autostainer Link 48 | OptiView DAB IHC Detection Kit | N/A |
Ab = antibody; CPS = combined positive score; IC = immune cells; ICI = immune checkpoint inhibition; IHC = immunohistochemistry; N/A = not applicable; SCCHN = squamous cell carcinoma of the head and neck; TC = tumor cells.